Court grants 10x Genomics’ motion in part in patent suit against NanoString

In an order posted to the site of the U.S. District Court for the District of Delaware, the court stated: “10x Genomics (TXG), Inc. and Prognosys Biosciences, Inc. sued NanoString Technologies, Inc.1 for patent infringement. Following a five-day trial, the jury found that NanoString willfully, directly, and indirectly infringed 10x’s asserted patents. The jury awarded 10x over twenty-five million dollars in lost profits and over six million dollars in lost royalties. NanoString has moved for judgment as a matter of law on invalidity, infringement, and damages or, in the alternative, for a new trial. 10x, on the other hand, has moved for entry of a permanent injunction, enhancement of damages, attorneys’ fees, supplemental damages, and pre-judgment and post-judgment interest… the Court denies NanoString’s motion and grants 10x’s motion in part.” The filing noted: “Bruker (BRKR) Corporation acquired NanoString following the filing of these motions. In this decision, the Court will refer to the defendants as NanoString.”